Philips bolsters cardiovascular ultrasound portfolio with Affiniti CVx launch

Royal Philips has launched AffinitiCVx to offer better support to cardiology departments in providing enhanced care to more patients with increased efficiency and throughput.

This is the latest addition to the company’s dedicated cardiovascular ultrasound solutions and is developed to scale up productivity.

It provides cardiologists with a tailored workflow by integrating with a common platform that was first released with the Philips’ premium cardiology ultrasound system, EPIQ CVx.

Affiniti CVx consists of a common configurable UI, a number of popular automated tools and the transducers. Additionally, TEE transducers have been added across the Affiniti CVx and EPIQ CVx systems.

Furthermore, the new system features AutoStrain technology, which is said to slash strain analysis time by as much as 70%.

These features will enable cardiology departments to standardise their ultrasound fleet for better management, simplify cross-platform clinician training and minimise the total cost of ownership, the company added.

Cardiologist and at PhilipsCardiology and Personal Health medical officer Dr.Alexandra Gonçalves said: “The Covid-19 pandemic has created an urgent need for nimble, user-friendly cardiac ultrasound solutions that can keep patients and healthcare providers safe while also generating the data needed to make confident decisions.

“With Release 7.0 of EPIQ CVx and AffinitiCVx, we’ve sharpened our focus on improving the cardiology experience by increasing the integration of our platforms to meet this demand.Taken together, these releases help cardiology teams work faster and with greater precision and efficiency so that they can deliver the best possible heart care.”

Philips is launching its new AffinitiCVx at At ESC 2020. The company is also releasing its 7.0 for EPIQ CVx cardiovascular ultrasound solutions, with upgrades to advance confidence in diagnosis and procedures, and offer enhanced the user experience.